Stay up to date on the latest oncology and nursing conferences.
Neoadjuvant, Adjuvant Nivolumab Improve EFS in Resectable NSCLC
October 21st 2023Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.
Liso-cel Demonstrates Rapid, Durable Responses in Patients with Relapsed/Refractory CLL/SLL
June 24th 2023The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
CDK4/6 Inhibitors May Be Better Suited in the Second-Line for Patients With ER+, HER2– Breast Cancer
June 21st 2023Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.